Low-dose doxycycline prevents inflammatory bone resorption in rats.

M.M Bezerra,G.A.C Brito,F.A.C Rocha,R.A Ribeiro

doi:10.1590/s0100-879x2002000500015

M.M Bezerra, G.A.C Brito + Show 2 more

Open Access

https://doi.org/10.1590/s0100-879x2002000500015

Copy DOI

Abstract

Matrix metalloproteinases (MMP) are considered to be key initiators of collagen degradation, thus contributing to bone resorption in inflammatory diseases. We determined whether subantimicrobial doses of doxycycline (DX) (< or =10 mg kg-1 day-1), a known MMP inhibitor, could inhibit bone resorption in an experimental periodontitis model. Thirty male Wistar rats (180-200 g) were subjected to placement of a nylon thread ligature around the maxillary molars and sacrificed after 7 days. Alveolar bone loss (ABL) was measured macroscopically in one hemiarcade and the contralateral hemiarcade was processed for histopathologic analysis. Groups of six animals each were treated with DX (2.5, 5 or 10 mg kg-1 day-1, sc, 7 days) and compared to nontreated (NT) rats. NT rats displayed significant ABL, severe mononuclear cell influx and increase in osteoclast numbers, which were significantly reduced by 5 or 10 mg kg-1 day-1 DX. These data show that DX inhibits inflammatory bone resorption in a manner that is independent of its antimicrobial properties.

Highlights

Matrix metalloproteinases (MMP) are considered to be key initiators of collagen degradation, contributing to bone resorption in inflammatory diseases
We determined whether subantimicrobial doses of doxycycline (DX) (£10 mg kg-1 day-1), a known MMP inhibitor, could inhibit bone resorption in an experimental periodontitis model
NT rats displayed significant Alveolar bone loss (ABL), severe mononuclear cell influx and increase in osteoclast numbers, which were significantly reduced by 5 or 10 mg kg-1 day-1 DX. These data show that DX inhibits inflammatory bone resorption in a manner that is independent of its antimicrobial properties

Summary

Introduction

Matrix metalloproteinases (MMP) are considered to be key initiators of collagen degradation, contributing to bone resorption in inflammatory diseases. We determined whether subantimicrobial doses of doxycycline (DX) (£10 mg kg-1 day-1), a known MMP inhibitor, could inhibit bone resorption in an experimental periodontitis model.

Results

Conclusion